Dyadic International (NASDAQ:DYAI) Stock Passes Above 50-Day Moving Average – Should You Sell?
by Jessica Moore · The Cerbat GemDyadic International Inc. (NASDAQ:DYAI – Get Free Report) shares passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.87 and traded as high as $1.60. Dyadic International shares last traded at $1.30, with a volume of 337,923 shares.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $3.00.
View Our Latest Report on Dyadic International
Dyadic International Trading Down 1.7%
The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.85. The stock has a market cap of $43.36 million, a price-to-earnings ratio of -5.17 and a beta of 1.15.
Dyadic International (NASDAQ:DYAI – Get Free Report) last issued its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. Equities analysts anticipate that Dyadic International Inc. will post 0.13 EPS for the current year.
Hedge Funds Weigh In On Dyadic International
Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its position in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the period. Marathon Capital Management raised its holdings in shares of Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of Dyadic International during the third quarter worth approximately $190,000. Institutional investors and hedge funds own 27.95% of the company’s stock.
Dyadic International Company Profile
Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.
The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.